<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120729">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531114</url>
  </required_header>
  <id_info>
    <org_study_id>RESET I-2D Trial</org_study_id>
    <nct_id>NCT01531114</nct_id>
  </id_info>
  <brief_title>PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus</brief_title>
  <acronym>RESET I-2D</acronym>
  <official_title>Prasugrel Or Ticagrelor In ST-Elevation Myocardial InfarcTion Patients With Diabetes Mellitus Requiring or Not Insulin Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gennaro Sardella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual antiplatelet therapy is essential in patients following ST-Elevation myocardial
      infarction (STEMI) with percutaneous coronary intervention (PCI) and drug eluting stent
      implantation. Current guidelines recommend prasugrel and ticagrelor in patients with STEMI
      undergoing primary PPCI. We sought to investigate the superiority antiplatelet effect in
      terms of PR level of loading dose (LD) of Prasugrel (60 mg) versus LD of Ticagrelor (180 mg)
      in diabetic patients with STEMI undergoing primary PCI at 1 and 2 hours post drug
      administration. Secondary end-points will be: PR level measured at 6 and 12 hours post study
      drugs administrationin hospital. All consecutive diabetic patients with STEMI undergoing
      PPCI with stent implantation will be considered for PR assessment at 1-2-6-12 h after the
      drug LD administration. All patients must will be naïve for platelet P2Y12 receptor
      inhibition therapy. A subanalysis will be performed between two study groups according to
      insulin treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the superiority antiplatelet effect in terms of PR level of loading dose (LD) of Prasugrel (60 mg) versus LD of Ticagrelor (180 mg) in diabetic patients with STEMI undergoing primary PCI at 2 hours post drug administration.</measure>
    <time_frame>1 and 2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PR level measured at 6 and 12 hours post study drugs administration.</measure>
    <time_frame>in hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>ST-Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Prasugrel loading dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to this arm to receive loading dose of prasugrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ticagrelor loading dose</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be randomized to this arm to receive loading dose of ticagrelor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <description>Patients will be randomized to this arm to receive loading dose of ticagrelor</description>
    <arm_group_label>Prasugrel loading dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>Patients will be randomized to this arm to receive loading dose of prasugrel</description>
    <arm_group_label>Prasugrel loading dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients

          -  acute coronary syndrome

          -  patients underwent to primary PCI

          -  naïve for platelet P2Y12 receptor inhibition therapy

        Exclusion Criteria:

          -  history of bleeding diathesis

          -  chronic oral anticoagulation treatment

          -  contraindications to antiplatelet therapy

          -  PCI or coronary artery bypass grafting (CABG) &lt; 3 months

          -  hemodynamic instability

          -  platelet count &lt; 100,000/μl

          -  hematocrit &lt; 30%

          -  creatinine clearance &lt; 25 ml/min

          -  Patients with a history of stroke

          -  contraindication for prasugrel administration

          -  patients weighing &lt; 60 kg

          -  patients treated with morphine

          -  &gt; 75 years of age.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept.of Cardiovascular Sciences,Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>February 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Gennaro Sardella</investigator_full_name>
    <investigator_title>Associate Professor in Cardiology</investigator_title>
  </responsible_party>
  <keyword>Diabetes mellitus</keyword>
  <keyword>antiplatelet effect</keyword>
  <keyword>prasugrel</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>STEMI</keyword>
  <keyword>Insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
